Sergio Fini

Sergio Fini

Auto-generated profile, based on publicly available information

Sergio Fini

UOL of Medical Genetics, Department of Reproduction and Growth and Department of Medical Science, Ferrara, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2008 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MBMatteo Bovolenta
Matteo Bovolenta
MNMarcella Neri
Marcella Neri
SFSergio Fini
Sergio Fini
MFMarina Fabris
Marina Fabris
CTCecilia Trabanelli
Cecilia Trabanelli
AFAlessandra Ferlini
Alessandra Ferlini
Background: The commonest pathogenic DMD changes are intragenic deletions/duplications which make up to 78% of all cases and point mutations (roughly 20%) detectable through direct sequencing. The remaining mutations (about 2%) are thought to be pure intronic rearrangements/mutations or 5'-3' UTR changes. In order to screen the huge DMD gene for all types of copy number variation mutations we designed a novel custom high density comparative genomic hybridisation array which contains the full genomic region of the DMD gene and spans from 100 kb upstream to 100 kb downstream of the 2.2 Mb DMD gene. Results: We studied 12 DMD/BMD patients who either had no detectable mutations or carried previously identified quantitative pathogenic changes in the DMD gene. We validated the array on patients with previously known mutations as well as unaffected controls, we identified three novel pure intronic rearrangements and we defined all the mutation breakpoints both in the introns and in the 3' UTR region. We also detected a novel polymorphic intron 2 deletion/duplication variation. Despite the high resolution of this approach, RNA studies were required to confirm the functional significance of the intronic mutations identified by CGH. In addition, RNA analysis identified three intronic pathogenic variations affecting splicing which had not been detected by the CGH analysis. Conclusion: This novel technology represents an effective high throughput tool to identify both common and rarer DMD rearrangements. RNA studies are required in order to validate the significance of the CGH array findings. The combination of these tools will fully cover the identification of causative DMD rearrangements in both coding and non-coding regions, particularly in patients in whom standard although extensive techniques are unable to detect a mutation.

13 September 2017 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
GPGiulia Parmeggiani
Giulia Parmeggiani
SBStefania Bigoni
Stefania Bigoni
BBBarbara Buldrini
Barbara Buldrini
GGGiampaolo Garani
Giampaolo Garani
LCLuigi Clauser
Luigi Clauser
SFSergio Fini
Sergio Fini
Reported here is the case of a 1.8-year-old boy with a 9.6- Mb deletion in 6q13q14.1 and an 11.2-Mb deletion in 6q21q22.31, ascertained through array CGH, as the result of a complex de novo chromosome rearrangement. The clinical picture of this patient is characterized by severe psychomotor delay, dysmorphic features, and some congenital defects. Although, as reported in the literature, phenotypes associated with 6q deletions may vary, an attempt was made to associate the patient's symptoms to either deletion, comparing them to previously reported cases. Only a limited specific correlation was found, probably due to the prevalence of very common symptoms.